Adhesion barrier gel Antiadgezin for degenerative lumbar spine disease

Abstract

Objective. To assess the effectiveness of the application of adhesion barrier gel Antiadgezin to prevent the development of cicatricial ad- hesive process and its complications in the spinal canal after decompression surgery for degenerative disease in the lumbar spine. Material and Methods. An open-label comparative randomized prospective clinical trial was conducted. The study involved 30 patients with degenerative lumbar spine disease who underwent decompression surgery. Patients were divided into two groups: in Group 1, gel Antiadgesin was injected during the spinal canal decompression, and in Group 2, the saline solution was injected. The severity of adhesive process was assessed according to MRI findings, and the severity of the pain syndrome and the degree of vital activity limitation were as- sessed by VAS and the Oswestry questionnaire in 2 weeks, 2 months and 1 year after surgery. Results. Application of gel Antiadgesin allows reducing the probability of cicatricial process development in the spinal canal up to 35 % in comparison with the control group. The intensity of the cicatricial adhesive process development decreases by more than 3 times with the application of gel Antiadgesin. Reduction of pain syndrome according to VAS and restoration of physical activity are significantly more pronounced during the first weeks in Group 1. Infectious complications or allergic reactions in the study groups were not noted. Conclusion. The use of adhesive barrier gel Antiadgesin during surgery reduces the likelihood of cicatricial adhesive process development in the spinal canal, which allows decreasing pain intensity and preventing disability in the postoperative period.

Keywords

• gel antiadgesin
• adhesion
• adhesion barrier
• degenerative diseases of the spine
• spinal canal decompression